☰

Stephane Wong, Ph.D. - Publications

Affiliations: 
2004 University of California, Los Angeles, Los Angeles, CA 
Area:
Molecular Biology, Oncology
Tree Info Grants Similar researchers PubMed Report error

26 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Pulsipher MA, Han X, Quigley M, Kari G, Rives S, Laetsch TW, Myers GD, Hiramatsu H, Yanik GA, Qayed M, Driscoll T, Boyer MW, Stefanski H, Buchner J, Baruchel A, ... ... Wong S, et al. Abstract CT077: Potential utility of minimal residual disease (MRD) to identify relapse in pediatric and young adult (AYA) B-cell acute lymphoblastic leukemia (B-ALL) patients treated with tisagenlecleucel Clinical Trials. DOI: 10.1158/1538-7445.Sabcs18-Ct077  0.305
2019 Awasthi R, Mueller KT, Yanik GA, Tam CS, Rives S, McGuirk JP, Pulsipher MA, Boyer MW, Jaeger U, Baruchel A, Myers GD, Borchmann P, Schuster SJ, Stefanski H, Bishop M, ... ... Wong S, et al. Abstract CT237: Evaluation of in vivo chimeric antigen receptor (CAR) transgene levels in patients (pts) treated with tisagenlecleucel Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct237  0.309
2018 Mahon FX, Boquimpani C, Kim DW, Benyamini N, Clementino NCD, Shuvaev V, Ailawadhi S, Lipton JH, Turkina AG, De Paz R, Moiraghi B, Nicolini FE, Dengler J, Sacha T, Takahashi N, ... ... Wong S, et al. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study. Annals of Internal Medicine. PMID 29459949 DOI: 10.7326/M17-1094  0.322
2018 Pulsipher MA, Han X, Quigley M, Kari G, Rives S, Laetsch TW, Myers GD, Hiramatsu H, Yanik GA, Qayed M, Driscoll T, Boyer MW, Stefanski H, Büchner J, Baruchel A, ... ... Wong S, et al. Molecular Detection of Minimal Residual Disease Precedes Morphological Relapse and Could be Used to Identify Relapse in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia Patients Treated with Tisagenlecleucel Blood. 132: 1551-1551. DOI: 10.1182/Blood-2018-99-115460  0.327
2016 Hughes TP, Boquimpani C, Kim D, Benyamini N, Clementino NCD, Shuvaev V, Ailawadhi S, Lipton JH, Turkina AG, Arias RDP, Moiraghi B, Nicolini FE, Dengler J, Sacha T, Takahashi N, ... ... Wong S, et al. Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with second-line nilotinib (NIL): First results from the ENESTop study. Journal of Clinical Oncology. 34: 7054-7054. DOI: 10.1200/Jco.2016.34.15_Suppl.7054  0.304
2015 Huang A, Salcius J, Wong C, Wong S, Wang S. International Scale (IS)-Standardized BCR-ABL1 Digital Polymerase Chain Reaction (dPCR) Assays Using ABL1, BCR, and GUS Control Genes for Measuring Deep Molecular Response (MR) in Chronic Myeloid Leukemia (CML) Blood. 126: 136-136. DOI: 10.1182/Blood.V126.23.136.136  0.321
2013 Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, ... ... Wong S, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. The New England Journal of Medicine. 369: 1783-96. PMID 24180494 DOI: 10.1056/Nejmoa1306494  0.345
2013 Kristof J, Bruening E, Wong S, Sankar S. Abstract 3491: Absolute quantification of EGFR activation and resistance mutations as well as copy number in circulating nucleic acids by droplet digital PCR. Cancer Research. 73: 3491-3491. DOI: 10.1158/1538-7445.Am2013-3491  0.317
2012 Kantarjian HM, Kim D, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo D, Abruzzese E, Rea D, Baccarani M, ... ... Wong S, et al. Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial Blood. 120: 915-915. DOI: 10.1182/Blood.V120.21.915.915  0.328
2012 Hochhaus A, Kim D, Pinilla-Ibarz J, Coutre Pl, Paquette R, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo D, Abruzzese E, Rea D, Baccarani M, ... ... Wong S, et al. Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial Blood. 120: 3763-3763. DOI: 10.1182/Blood.V120.21.3763.3763  0.345
2012 Kim D, Cortes JE, Pinilla-Ibarz J, Coutre Pl, Paquette R, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo D, Abruzzese E, Rea D, Baccarani M, ... ... Wong S, et al. Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial Blood. 120: 3749-3749. DOI: 10.1182/Blood.V120.21.3749.3749  0.322
2012 Mauro MJ, Cortes JE, Kim D, Pinilla-Ibarz J, Coutre Pl, Paquette R, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo DJ, Abruzzese E, Rea D, ... ... Wong S, et al. Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial Blood. 120: 3747-3747. DOI: 10.1182/Blood.V120.21.3747.3747  0.318
2012 Li J, Liu W, Yan Z, Fang P, Darwanto A, Pelak K, Toplin J, Anoe K, Spittle C, Galderisi C, Wong S. Next-Generation Sequencing of the BCR-ABL1 Kinase Domain and Neighboring Domains Associated with Therapy Resistance. Blood. 120: 2549-2549. DOI: 10.1182/Blood.V120.21.2549.2549  0.328
2012 Cortes JE, Kim D, Pinilla-Ibarz J, Coutre Pl, Paquette R, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, ... ... Wong S, et al. A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial Blood. 120: 163-163. DOI: 10.1182/Blood.V120.21.163.163  0.337
2011 O'Hare T, Zabriskie MS, Eide CA, Agarwal A, Adrian LT, You H, Corbin AS, Yang F, Press RD, Rivera VM, Toplin J, Wong S, Deininger MW, Druker BJ. The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Blood. 118: 5250-4. PMID 21908430 DOI: 10.1182/Blood-2011-05-349191  0.397
2011 Cortes JE, Kim D, Pinilla-Ibarz J, Coutre PDL, Chuah C, Nicolini FE, Paquette R, Apperley JF, DiPersio JF, Khoury HJ, Rea D, Talpaz M, DeAngelo DJ, Abruzzese E, Baccarani M, ... ... Wong S, et al. Initial Findings From the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I Mutation Blood. 118: 109-109. DOI: 10.1182/Blood.V118.21.109.109  0.315
2004 Wong S, McLaughlin J, Cheng D, Zhang C, Shokat KM, Witte ON. Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations. Proceedings of the National Academy of Sciences of the United States of America. 101: 17456-61. PMID 15505216 DOI: 10.1073/Pnas.0407061101  0.558
2004 Wong S, Witte ON. The BCR-ABL story: bench to bedside and back. Annual Review of Immunology. 22: 247-306. PMID 15032571 DOI: 10.1146/Annurev.Immunol.22.012703.104753  0.517
2004 Kharas MG, Deane JA, Wong S, O'Bosky KR, Rosenberg N, Witte ON, Fruman DA. Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells. Blood. 103: 4268-75. PMID 14976048 DOI: 10.1182/Blood-2003-07-2193  0.539
2003 Wong S, McLaughlin J, Cheng D, Shannon K, Robb L, Witte ON. IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease. Proceedings of the National Academy of Sciences of the United States of America. 100: 11630-5. PMID 14500898 DOI: 10.1073/Pnas.2035020100  0.452
2003 Wong S, McLaughlin J, Cheng D, Witte ON. Cell context-specific effects of the BCR-ABL oncogene monitored in hematopoietic progenitors. Blood. 101: 4088-97. PMID 12521991 DOI: 10.1182/Blood-2002-11-3376  0.528
2002 Le LQ, Kabarowski JH, Wong S, Nguyen K, Gambhir SS, Witte ON. Positron emission tomography imaging analysis of G2A as a negative modifier of lymphoid leukemogenesis initiated by the BCR-ABL oncogene. Cancer Cell. 1: 381-91. PMID 12086852 DOI: 10.1016/S1535-6108(02)00058-2  0.596
2002 Era T, Wong S, Witte ON. Analysis of Bcr-Abl function using an in vitro embryonic stem cell differentiation system. Methods in Molecular Biology (Clifton, N.J.). 185: 83-95. PMID 11769015 DOI: 10.1385/1-59259-241-4:83  0.409
2001 Wong S, Witte ON. Modeling Philadelphia chromosome positive leukemias. Oncogene. 20: 5644-59. PMID 11607816 DOI: 10.1038/Sj.Onc.1204638  0.499
2000 Lim YM, Wong S, Lau G, Witte ON, Colicelli J. BCR/ABL inhibition by an escort/phosphatase fusion protein. Proceedings of the National Academy of Sciences of the United States of America. 97: 12233-8. PMID 11027300 DOI: 10.1073/Pnas.210253497  0.543
1997 Afar DE, Han L, McLaughlin J, Wong S, Dhaka A, Parmar K, Rosenberg N, Witte ON, Colicelli J. Regulation of the oncogenic activity of BCR-ABL by a tightly bound substrate protein RIN1. Immunity. 6: 773-82. PMID 9208849 DOI: 10.1016/S1074-7613(00)80452-5  0.529
Show low-probability matches.